Tissue factor pathway inhibitor is required for cerebrovascular development in mice

Tracking no: BLD-2020-006054R1

Susan Maroney (Versiti Blood Research Institute, United States) Randal Westrick (Oakland University, United States) Audrey Cleuren (University of Michigan, United States) Nicholas Martinez (Versiti, United States) Amy Siebert (Versiti, United States) Mark Zogg (Versiti Blood Research Institute, United States) David Ginsburg (University of Michigan Medical Center, United States) Hartmut Weiler (Blood Research Institute / Versiti, United States) Alan Mast (Versiti, United States)

Abstract:
Tissue factor pathway inhibitor (TFPI) inhibits proteases in the blood coagulation cascade that lead to the production of thrombin, including prothrombinase (FXa/FVa), the catalytic complex that directly generates thrombin. Thus, TFPI and FV are directly linked in regulating the procoagulant response. Studies using knock-out mice indicate that TFPI and FV are necessary for embryogenesis, but their contributions to vascular development are unclear. We performed extensive histological analyses of $Tfpi^{-/-}$ and $Tfpi^{-/-}$ $F5^{-/-}$ mouse embryos to investigate the importance of the interplay between TFPI and FV in regulating hemostasis and vascular development during embryogenesis. We observed normal tissue development throughout $Tfpi^{-/-}$ embryos except in the central nervous system. The central nervous system displayed stunted brain growth, delayed development of the meninges, and severe vascular pathology characterized by the formation of glomeruloid bodies surrounding areas of cellular death, fibrin deposition, and hemorrhage. Removing FV from the $Tfpi^{-/-}$ embryos completely ameliorated their brain pathology, suggesting that TFPI dampens FV-dependent procoagulant activity in a manner that modulates cerebrovascular development. Thus, we have identified a previously unrecognized role for TFPI activity within the central nervous system. This TFPI activity likely diminishes an effect of excess thrombin activity on signaling pathways that control cerebral vascular development.

Conflict of interest: COI declared - see note

COI notes: Conflict of Interest Statement: AEM receives research funding from Novo Nordisk and has received honoraria for serving on Novo Nordisk Advisory Boards. The other authors have declared that no conflict of interest exists.

Preprint server: No;

Author contributions and disclosures: S.A.M. Designed research, performed research, analyzed data and wrote the paper. R.J.W designed research, analyzed data and wrote the paper. A.C.C. performed research and wrote the paper. N.D.M performed research. A.E.S. analyzed data and wrote the paper. M.Z. performed research. D.G. analyzed data and wrote the paper. H.W. analyzed data and wrote the paper. A.E.M. designed research, analyzed data, and wrote the paper.

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement: The mouse lines used in this study are available publically. We will provide other reagents and protocols to other investigators upon request.

Clinical trial registration information (if any):

Tissue Factor Pathway inhibitor is required for cerebrovascular development in mice

Susan A. Maroney,[1] Randal J. Westrick,[2,3] Audrey C. Cleuren,[3] Nicholas D. Martinez,[1] Amy E. Siebert,[1] Mark Zogg,[1] David Ginsburg,[3,5] Hartmut Weiler[1,6] and Alan E. Mast[1,7*]

[1]Versiti Blood Research Institute, Milwaukee, WI 53226

[2]Department of Biological Sciences and Center for Data Science and Big Data Analytics, Oakland University, Rochester, MI 48309

[3]Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109

[4]Departments of Internal Medicine, Human Genetics, and Pediatrics, University of Michigan, Ann Arbor, MI 48109

[5]Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109

[6]Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226

[7]Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI 53226

Running Head: TFPI in cerebrovascular development

Abstract word count: 204
Text word count: 3,979
Number of Figures: 7
Number of Tables: 0
Number of References: 54

*Alan E. Mast
Blood Research Institute
Versiti
PO Box 2178
Milwaukee, WI 53201-2178
Tel: 414-937-6310
Email: aemast@versiti.org

Key Points

1. *Tfpi*$^{-/-}$ embryos have severe vascular pathology with associated cellular death in the central nervous system but not in other organs.

2. Removing FV from the *Tfpi*$^{-/-}$ embryos completely ameliorates the central nervous system pathology.

Abstract

Tissue factor pathway inhibitor (TFPI) inhibits proteases in the blood coagulation cascade that lead to the production of thrombin, including prothrombinase (FXa/FVa), the catalytic complex that directly generates thrombin. Thus, TFPI and FV are directly linked in regulating the procoagulant response. Studies using knock-out mice indicate that TFPI and FV are necessary for embryogenesis, but their contributions to vascular development are unclear. We performed extensive histological analyses of *Tfpi*$^{-/-}$ and *Tfpi*$^{-/-}$ *F5*$^{-/-}$ mouse embryos to investigate the importance of the interplay between TFPI and FV in regulating hemostasis and vascular development during embryogenesis. We observed normal tissue development throughout *Tfpi*$^{-/-}$ embryos except in the central nervous system. The central nervous system displayed stunted brain growth, delayed development of the meninges, and severe vascular pathology characterized by the formation of glomeruloid bodies surrounding areas of cellular death, fibrin deposition, and hemorrhage. Removing FV from the *Tfpi*$^{-/-}$ embryos completely ameliorated their brain pathology, suggesting that TFPI dampens FV-dependent procoagulant activity in a manner that modulates cerebrovascular development. Thus, we have identified a previously unrecognized role for TFPI activity within the central nervous system. This TFPI activity likely diminishes an effect of excess thrombin activity on signaling pathways that control cerebral vascular development.

Introduction

Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type serine protease inhibitor that directly inhibits factor Xa (FXa), and provides FXa-dependent feedback inhibition of the tissue factor (TF)-FVIIa catalytic complex, which initiates coagulation through activation of factors IX and X.[1-4] The inhibitory activity of TFPI is mediated by simultaneous inhibition of TF-FVIIa and FXa in the TF-FVIIa-FXa ternary complex.[5] By inhibiting these blood coagulation proteases, TFPI also controls intracellular signaling events mediated by protease-activated receptor (PARs) that modulate vascular development,[6] cellular migration,[7,8] and tumor angiogenesis.[9]

The importance of TFPI in development is illustrated by the embryonic death observed in homozygous mice lacking the first Kunitz (K1) domain of TFPI (*Tfpi^tm1Gjb*; *Tfpi^−/−*).[10] On a mixed 129-C57BL/6 genetic background, about 60% of *Tfpi^−/−* embryos die during mid-gestation between E9.5 and E11.5. The remainder dies later in gestation between E12.5 and birth. Mid-gestational embryonic death is associated with apparent vascular abnormalities of the yolk sac with associated hemorrhage. The later stage embryos had normal vasculature but developed hepatic fibrin deposition suggestive of a consumptive coagulopathy. Rare intravascular thrombi were also observed in the brain of some embryos, while massive hemorrhage with significant loss of brain matter was observed in others.[10,11] However, the origin of these brain phenotypes remains unclear.

TFPI also inhibits the FVa-FXa catalytic complex (prothrombinase),[12] which converts prothrombin to thrombin. Thrombin is the terminal blood coagulation protease that produces a fibrin-rich blood clot. Thrombin also is a potent activator of PARs on platelets and

4

endothelium.[13] Prothrombinase inhibition is mediated by multiple interactions between TFPI and prothrombinase that directly inhibit the ability of prothrombinase to convert prothrombin to thrombin,.[12,14] as well as by TFPI sterically constraining thrombin from fully cleaving the FV B-domain.[15] Thus, TFPI and FV are directly linked in the biological regulation of thrombin production and availability for PAR activation. For example, PAR4 (*F2rl3*) is the major thrombin-activated PAR on mouse platelets.[16] Its absence partially rescues T*fpi*$^{-/-}$ mice from embryonic lethality, implicating TFPI as a physiologically relevant inhibitor of thrombin-dependent platelet procoagulant activity during murine embryogenesis.[17]

Homozygosity for FV deletion (*F5*$^{-/-}$) also results in embryonic lethality in mice.[18] Deranged vascular development is present in *F5*$^{-/-}$ yolk sacs contributing to mid-gestational death. Similar to *Tfpi*$^{-/-}$ embryos, a portion of *F5*$^{-/-}$ embryos survive this mid-gestation bottleneck, developing normally until succumbing perinatally from severe intra-abdominal hemorrhage induced by birthing trauma. However, the global vasculature in these embryos appears otherwise intact.[18] Thus, FV is necessary for surviving the hemostatic challenges associated with birth, but the contribution of FV to embryonic vascular development is not fully understood.

In addition to the *F5*$^{-/-}$ mouse, several *F5* transgenic mouse models have been developed.[19,20] Combined with the *Tfpi*$^{-/-}$ mouse, these models provide an opportunity to further examine contributions of the blood coagulation system to hemostasis and vascular development during embryogenesis. Here, we have performed extensive, detailed histological analyses of multiple tissues from *Tfpi*$^{-/-}$ embryos and identified a role for TFPI-dependent inhibition of FV-driven coagulation necessary for proper cerebral vascular development.

5

Materials and Methods

Generation of mice and embryos. Mice heterozygous for the TFPI-K1 null allele

(*Tfpi^{tm1Gjb}*;*Tfpi^{+/−}*)[10] were a generous gift from Dr. George Broze, Jr. (Washington University, St

Louis). *Tfpi^{+/−}* mice were backcrossed to C57BL/6J (stock #000664, The Jackson Laboratory) for

more than 10 generations, and maintained as an independent line within our mouse colony.

Timed matings were performed by crossing *Tfpi^{+/−}* male and female mice. Mice with a

completely FV null allele (*F5^{tm1Dgi}* stock #004078, The Jackson Laboratory, *F5^−*) and transgenic

mice with BACs expressing FV under control of either the murine hepatocyte-specific albumin

promoter FV (B6;SJL-Tg(Alb-F5)2Dgi/J stock #007244, The Jackson Laboratory, *F5^{LiverTg}*) or

the murine platelet factor 4 promoter (B6;SJL-Tg(Cxcl4-F5)1Dgi/J stock #007243, The Jackson

Laboratory, *F5^{PltTg}*) have been previously described.[20] Genotyping for *Tfpi^−*, *F5^−*, *F5^{LiverTg}*, and

F5^{PltTg} were performed by PCR analysis of tail DNA using primers as described.[10,20]

Crossbreeding experiments using *F5^{−/−}* mice carrying liver- or platelet-specific transgenes were

performed to create *F5^{−/−} F5^{LiverTg}* and *F5^{−/−} F5^{PltTg}* mice. *F5^{−/−}* mice are viable when they co-

inherit the *F5^{LiverTg}* or *F5^{PltTg}*.[20] *F5^{−/−} F5^{LiverTg}* and *F5^{−/−} F5^{PltTg}* were separately bred onto the *Tfpi*

deficient mouse background to produce *F5^{−/−} F5^{LiverTg}* and *F5^{−/−} F5^{PltTg}* embryos that are also

Tfpi^{−/−}.

Tissue retrieval. Pregnant females were anesthetized using isofluorane inhalant. The uterus

containing the embryos was removed. The mother was immediately euthanized by anesthetic

overdose and cervical dislocation. The embryos were retrieved and processed according to NIH

Guidelines for Euthanasia for Rodent Fetuses and Neonates

[https://oacu.oir.nih.gov/sites/default/files/uploads/arac-

6

guidelines/b4_rodent_euthanasia_pup.pdf]. Each embryo was separated from the uterus and placenta, washed in 4°C phosphate buffered saline (PBS) and placed in 4°C 10% formaldehyde buffered with PBS. After 7 days, the embryo midline was sagittally transected and each half processed for histology. In some embryos, brains were coronally sectioned for histological evaluation. The gestational age of embryos was determined by measuring crown to rump length, Theiler's stage criteria,[21] and histological examination of lung, kidney, and brain.

Histology. Paraffin-embedded tissue was cut in 5 µm sections and visualized using H&E, trichrome, or Martius Scarlet Blue (MSB) staining. Primary immunohistochemistry antibodies included anti-laminin-1 (#L9393 Sigma-Aldrich, St. Louis, MO) and anti-fibrinogen (#YNGMFBG7S Accurate Chemical & Scientific Corp, Westbury, NY). Species specific-IgG comparable to the test antibodies served as controls. Secondary labeling used species specific ImmPRESS® (HRP) polymers (#MP-7405 and #MP-7401 Vector Laboratories, Burlingame, CA) followed by detection with NovaRed (#SK-4805 Vector Laboratories) and counterstaining with hematoxylin (#H-3401 Vector Laboratories). Immunofluorescent staining was performed using anti-laminin-1(#L9393 Sigma-Aldrich, St. Louis, MO), anti-thrombomodulin (#AF-3894 R&D Systems, Minneapolis, MN), anti-platelet-derived growth factor receptor-β (Pdgfrβ) (#LS-C88709 LifeSpan Biosciences, Seattle, WA), anti-microglial ionized calcium binding adapter molecule-1 (Iba-1) (#019-19741 Waco, Richmond, VA), and a polyclonal rabbit antibody to the extracellular domain of mouse G protein coupled receptor 124 (Gpr124, a gift from Dr. Calvin Kuo, Stanford University). Secondary antibodies with a fluorescent conjugate at wavelength 568, 594, or 647 were from Jackson ImmunoResearch Labs (West Grove, PA). Species specific-IgG comparable to the test antibodies served as controls. A Motic Easy scan imaging system (Motic

7

Inc., LTD, Hong Kong) scanned immunohistochemistry slides. A Nikon Eclipse Ti2 inverted microscope with a DS-Ri2 high speed color camera using a low magnification 40x/0.95 or a high magnification 100x oil/1.45 numerical aperture oil objective (Nikon Instruments Inc., Melville, NY) acquired immunofluorescent images. Images were analyzed with the Nikon NIS-Elements software platform and processed with Imaris multi-channel microscopy software (Bitplane Inc., Concord, MA). Image formatting was performed in Adobe Photoshop CS-6 and Adobe Illustrator CS-6. (Adobe, San Jose, CA).

Study approval. The Institutional Animal Care and Use Committees of the Medical College of Wisconsin and the University of Michigan approved all animal experiments.

8

Results

$Tfpi^{-/-}$ embryos exhibited stunted brain development with cerebrovascular anomalies, hemorrhage, and cellular death. Microscopic examination of the brains from E15.5 $Tfpi^{+/+}$ embryos stained with hematoxylin and eosin (H&E) revealed age-appropriate brain development. We observed normal brain architecture that filled the calvarium and exhibited normal growth of the choroid plexus. In contrast, embryonic brains from $Tfpi^{-/-}$ littermates were smaller and did not fill the calvarium. The choroid plexus was underdeveloped, and there were numerous enlarged, misshapen blood vessels throughout the brain parenchyma (Fig. 1A and Fig. S1A). Examination of sections stained with trichrome or MSB identified the enlarged vessels observed with H&E stain to be well-demarcated, multi-focal vascular structures resembling renal glomeruli known as glomeruloid bodies (Fig. 1B). Glomeruloid bodies are a diagnostic feature of the brain cancer, glioblastoma multiforme.[22,23] In contrast to the architecture of glomeruloid bodies, vasculature of $Tfpi^{+/+}$ embryos had parallel walls lined with endothelial cells and often contain red blood cells. (Fig. S1B). Large areas with hemorrhage and cellular death were most readily observed in MSB stained tissue. These areas were encircled with glomeruloid bodies and appeared to coincide with their formation (Fig. 1C). Glomeruloid bodies were present in the brains of 12 of 12 $Tfpi^{-/-}$ embryos obtained from 7 litters between E12.5 and E16.5, but were not present in any of 50 $Tfpi^{+/+}$ or $Tfpi^{+/-}$ embryos, indicating that deletion of the K1 domain of TFPI results in complete penetrance of this cerebrovascular phenotype in homozygous carriers.

Glomeruloid bodies in $Tfpi^{-/-}$ brain had fibrin(ogen) deposition and endothelial cell hyperplasia. The MSB stained brain tissue from the $Tfpi^{-/-}$ embryos had red to pink areas, suggesting fibrin deposition (Fig. 1B). This was confirmed by immunohistochemical studies

9

identifing fibrin(ogen) inside the glomeruloid bodies, within the brain parenchyma surrounding the glomeruloid bodies, and within areas of cellular death (Fig. 2A). Immunohistochemistry for laminin, a vascular basement membrane protein,[24] clearly delineated the glomeruloid bodies within brain parenchyma (Fig. 2B). Immunofluorescent studies co-staining for laminin and the endothelial marker thrombomodulin were used to further examine brain vasculature (Fig. 2C). The *Tfpi*[+/+] cerebral vasculature was well-organized with endothelial cells lining the vessel lumen surrounded by a well-organized laminin-stained basement membrane. Laminin staining of the *Tfpi*[−/−] brain highlighted the enlarged multi-lobular and thin-walled structure of the glomeruloid bodies, while thrombomodulin staining was disorganized, indicating endothelial cell disarray. These characteristics are similar to those described for glomeruloid bodies present in glioblastoma multiforme, which are characterized by aggregates of focally anastomosing capillaries with narrow lumina and endothelial cell hyperplasia.[23]

**

Tfpi[−/−] **embryos had glomeruloid bodies in multiple areas of the brain and spinal cord but not in other vascular beds.** Examination of sagittal sections of *Tfpi*[−/−] embryonic brain revealed extensive pathology in the midbrain (Fig 2B). Coronal sectioning of the brain was then performed to further define affected regions of the brain (Fig. 3) with contrasting coronal sections of *Tfpi*[+/+] embryo brains illustrating normal vascular development (Fig S2). These studies found that *Tfpi*[−/−] embryos also developed glomeruloid bodies within the forebrain and the hindbrain indicating that multiple areas of the brain were affected by this altered vascularization process (Fig 3A). Coronal sections of the *Tfpi*[−/−] embryonic brain also identified altered vasculature along the pial surface, within the subventricular zone, and within the lateral ganglionic eminence of the forebrain (Fig. 3B). Glomeruloid bodies also were present within the

10

spinal cord (Fig. 3B). In contrast, other tissues had normal growth, architecture, and vasculature (Fig. S3). Thus, the formation of glomeruloid bodies in $Tfpi^{-/-}$ embryos was limited to the embryonic central nervous system (CNS), indicating a tissue-specific etiology for these defects.

The pia mater vasculature was disorganized in E15.5 $Tfpi^{-/-}$ embryos. The specificity of the vascular defects for the CNS suggested a role of TFPI on the unique angiogenic development of vasculature in the brain and spinal cord.[25] Therefore, vessel sprouting and growth from the perineural vascular plexus (PNVP) was examined. Immunohistochemical staining for laminin highlighted differences between the well-organized vasculature invading from the PNVP into the brain parenchyma in the $Tfpi^{+/+}$ embryo and the irregular architecture of the invading vessels in the $Tfpi^{-/-}$ embryo. The $Tfpi^{-/-}$ vasculature developed glomeruloid bodies immediately adjacent to the pia mater as vessels penetrated the brain parenchyma (Fig. 4A and B). Abnormal meningeal development also was evident within the $Tfpi^{-/-}$ embryos. All three layers of the meninges were present, but in some instances the layers were less defined than those observed in $Tfpi^{+/+}$ littermates, suggesting a possible delay in their growth and development (Fig. 4B). In areas with abnormal pia mater vasculature, the vasculature of the arachnoid mater also appeared developmentally delayed with poor definition of its two layers (Fig. 4A and B).

Glomeruloid bodies were present in E12.5 $Tfpi^{-/-}$ embryos. The embryonic brain undergoes active angiogenesis at E12.5 when vessels sprouting from the PNVP invade the neocortex and migrate radially towards the subventricular zone.[26] The brains from $Tfpi^{-/-}$ embryos were examined at E12.5 for vascular pathology during this critical time of cortical angiogenesis (Fig. S4). Hyperplasia of the pial vasculature with adjacent abnormal vasculature was present within

11

the brain parenchyma (Fig. S4B and C). Glomeruloid bodies were localized near the wall of the fourth ventricle and within the midbrain region, where they surrounded an area of cellular death (Fig. S4B). Thus, the lack of TFPI is associated with defects in the early stages of cerebral vascular angiogenesis initiated from the PNVP.

Pericytes and microglial cells were localized to glomeruloid bodies in the *Tfpi*[−/−] embryo.
The cerebral vasculature has more pericytes than other vascular beds,[27,28] and pericytes stained with PDGFR-β were readily observed lining cerebral vessels in the *Tfpi*[+/+] embryo (Fig. 5A). Abundant pericytes were associated with endothelial cells of glomeruloid bodies in *Tfpi*[−/−] embryos (Fig. 5A). Interestingly, the staining pattern for PDGFR-β was more localized and punctate in pericytes within glomeruloid bodies than in pericytes of normal vasculature. This altered staining pattern is perhaps another consequence of the abnormal vascular development within the glomeruloid body, although its significance remains to be determined. Microglial cells enter the brain between E8.5-E9.5, are the only resident immune cell found in the healthy brain parenchyma, and persist in the brain throughout adulthood with self-renewal capabilities independent of hematopoietic progenitor cells.[29,30] Microglia were examined in *Tfpi*[−/−] embryos because they play an important role in angiogenesis within the brain, including sprouting, migration, anastomosis, and vascular refinement.[31] Microglial cells localized to both normal vasculature in the *Tfpi*[+/+] embryos and the glomeruloid bodies in *Tfpi*[−/−] embryos with no major differences in appearance or abundance (Fig. 5B).

Glomeruloid bodies did not form in *Tfpi*[−/−] embryos lacking FV. In mice, the procoagulant cofactor, FV, is produced in distinct plasma and platelet pools.[20] *F5*[−/−] embryos can survive to

12

adulthood with transgenes that specifically express FV in either the liver, to produce plasma FV ($F5^{LiverTg}$), or in megakaryocytes, to produce platelet FV ($F5^{PltTg}$).[20] We have previously observed that $Tfpi^{-/-}$ embryos survive to adulthood when they completely lack FV expression at their endogenous locus ($F5^{-/-}$), while expressing either plasma or platelet FV via $F5^{LiverTg}$ or $F5^{PltTg}$.[32] Therefore, we considered a potential role for the interaction between TFPI and FV in cerebrovascular development. $F5^{-/-}$ $Tfpi^{-/-}$ mice carrying $F5^{LiverTg}$ or $F5^{PltTg}$ were crossed with $F5^{+/-}$ $Tfpi^{+/-}$ mice for timed matings with embryonic harvest at approximately E15.5. Four litters from each type of transgenic mating were collected, containing a total of 53 embryos. A pathologist blinded to the genotype of the embryos examined the brains for the presence of glomeruloid bodies and associated pathology. In each of the 21 $F5^{+/-}$ $Tfpi^{+/-}$ embryos, brain tissue appeared normal. In contrast, each of the 11 $F5^{+/-}$ $Tfpi^{-/-}$ embryos, regardless of FV transgenic line, were histologically indistinguishable from $Tfpi^{-/-}$ embryos when evaluated with trichrome, fibrinogen and laminin staining (Figs. 6A and B), confirming the 100% penetrance of this phenotype in $Tfpi^{-/-}$ embryos. In contrast, glomeruloid bodies and associated brain pathology were totally absent in the five $F5^{-/-}$ $Tfpi^{-/-}$ embryos that did not express a FV transgene as they had normal vasculature within the brain parenchyma and pia-brain interface (Figs. 6A and B). This indicates that FV is required for the development of glomeruloid bodies in $Tfpi^{-/-}$ embryos.

The absence of platelet FV prevented glomeruloid body formation in $Tfpi^{-/-}$ embryos. The $F5^{PltTg}$ produces ~5% normal platelet FV and no plasma FV.[20] No glomeruloid bodies were present in the brain of the single $F5^{-/-}$ $F5^{PltTg}$ $Tfpi^{-/-}$ embryo present among the 53 obtained from the above crosses. The only lesion identified was a very small micro-hemorrhage. This suggested that expression of circulating FV above ~5% normal levels was necessary for the formation of

13

glomeruloid bodies in the brain of $Tfpi^{-/-}$ embryos. $F5^{LiverTg}$ produces ~45% normal levels of plasma FV and no platelet FV.[20] Five of the 53 embryos were $F5^{-/-}$ $Tfpi^{-/-}$ and carried the $F5^{LiverTg}$. These embryos had either no or rare glomeruloid bodies in the brain (Fig. 6C). Since all the $F5^{+/-}$ $Tfpi^{-/-}$ embryos had glomeruloid body formation with severe secondary brain pathology and $F5^{-/-}$ $F5^{LiverTg}$ mice primarily differ from $F5^{+/-}$ mice in that they do not produce platelet FV, this finding suggests that lack of platelet FV ameliorates the formation of glomeruloid bodies in the brain of $Tfpi^{-/-}$ embryos.

Gpr124 was expressed in vasculature of glomeruloid bodies. The absence of glomeruloid bodies and associated brain pathology in $Tfpi^{-/-}$ embryos lacking FV suggests that excess thrombin produced by prothrombinase drives the phenotype. Mice with global or endothelial-specific deletion of Gpr124 (also called tumor endothelial marker 5) succumb to embryonic lethality with abnormal angiogenesis and production of glomeruloid bodies in the forebrain and spinal cord that mimics the vascular phenotype observed in the $Tfpi^{-/-}$ embryos.[33] Thrombin has been reported to cleave an N-terminal 60 kDa fragment of the extracellular domain of Gpr124.[34] Therefore, we hypothesized that excess thrombin production in the $Tfpi^{-/-}$ embryos results in proteolytic inactivation of Gpr124, which contributes to the similar phenotypes observed in these two mouse models. Examination of vessel sprouting and growth from the PNVP of $Tfpi^{+/+}$ and $Tfpi^{-/-}$ littermates were examined using dual fluorescent staining for the extracellular domain of Gpr124 and thrombomodulin (Fig. 7). Abundant staining of Gpr124 was observed within all vessels, including those in glomeruloid bodies, suggesting that degradation of Gpr124 is not responsible for the production of glomeruloid bodies in the $Tfpi^{-/-}$ mice.

14

Discussion

We have demonstrated that *Tfpi*[−/−] mouse embryos have stunted brain growth and delayed meningeal development during late-gestation. The stunted brain growth was associated with severe vascular pathology in the parenchyma of the forebrain, midbrain, hindbrain, and spinal cord characterized by glomeruloid bodies surrounding areas of cellular death, fibrin deposition, and hemorrhage. Thus, absence of the K1 domain of the anticoagulant protein TFPI is associated with a tissue-specific cerebrovascular phenotype that may contribute to the late gestational embryonic death of *Tfpi*[−/−] embryos.

Tfpi[−/−] embryos also had abnormally developed meninges during late-gestation with incomplete demarcation of the vascular and connective tissue layers of the arachnoid mater, disorganized vasculature within the pia mater, and formation of glomeruloid bodies upon vascular penetration from the PNVP into the adjacent brain parenchyma. Unlike other tissues that create vessels via vasculogenesis, the brain develops its vascular bed by angiogenic sprouting from the PNVP followed by extensive pruning and regression to form the final functional vasculature.[25,35,36] Since this activity of TFPI was specific to the CNS, and there was normal vascular development within other tissues, our findings suggest that TFPI modulates vascular development occurring through angiogenesis, but not through vasculogenesis.

Pericytes and microglial cells migrate from the yolk sac to the CNS before neurovascular development. They play an important role in angiogenesis, blood brain barrier integrity, and contribute to the production and deposition of laminin into the basement membrane.[37-39] Thus, they provide vascular support during development as well as expressing TFPI.[40,41] The *Tfpi*[−/−]

15

embryonic brain had both cell types present, indicating that the vascular pathology was not due to the absence of either of these critical cell lineages.

FV is a cofactor for FXa in prothrombinase, the proteolytic complex responsible for converting prothrombin to thrombin in the coagulation cascade. Development of pathology within the brain of late gestation $Tfpi^{-/-}$ embryos required the presence of FV, as the vascular lesions and associated pathology were completely absent in $Tfpi^{-/-}$ embryos lacking endogenous FV. This striking finding strongly suggests that TFPI dampens FV-dependent production of thrombin in a manner that modulates cerebrovascular development. Interestingly, platelet FV appeared to influence the phenotype, as $F5^{+/-}$ $Tfpi^{-/-}$ embryos, which expressed 50% FV levels in both the plasma and the platelet, developed severe brain pathology, while $F5^{-/-}$ $Tfpi^{-/-}$ embryos carrying $F5^{LiverTg}$, which have 45% plasma FV and no platelet FV, had normal brain development and cerebral vasculature with only rare vascular defects observed in two of five embryos. Therefore, the effect of TFPI on cerebral vasculature development appears to be mediated through its ability to diminish the generation of excess thrombin activity, rather than directly inhibit the upstream coagulation catalytic complexes, TF-FVIIa or TF-FVIIa-FXa, which mediate signaling events through PAR1 and PAR2 that modulate tumor angiogenesis.[8,9,42,43]

Although the glomeruloid body CNS phenotype requires the presence of FV, the CNS has higher amounts of TF than other tissues.[44] Thus, TFPI may diminish thrombin generation in the developing brain through its inhibition of TF-FVIIa activity and consequent dampening of downstream thrombin production,[1] a concept supported by the normal appearance of E17.5 $Tfpi^{-/-}$ embryos lacking FVII.[11] Alternatively, TFPI also directly inhibits early prothrombinase

16

activity, which is mediated, in part, by a tight-binding interaction between a basic region near the C-terminus of TFPIα and an acidic region in the B-domain of FV.[12,14] Support of a role for direct inhibition of prothrombinase by TFPI in modulation of vascular development is provided by previous findings showing the C-terminal region of TFPIα inhibits proliferation of cultured endothelial cells[45,46] and angiogenesis in a murine hind limb model.[47] Further, there are multiple, well-characterized differences in the production and tissue expression of TFPI[48,49] and FV[20,50] between mice and humans. Additional studies are needed to specifically define how different TFPI anticoagulant activities modulate thrombin production in the developing brain and how our findings in mice may apply to cerebrovascular development in humans.

Thrombin is a major activator of PAR receptors, which are expressed in developing vasculature.[51,52] Indeed, it has been suggested that developing vasculature senses thrombin and other coagulation factors in a manner that orchestrates the formation and remodeling of embryonic blood vessels.[6] Thus, altered activation of endothelial PARs by excess thrombin may contribute to the vascular development defects observed in *Tfpi*[−/−] embryos in a manner that is not well understood. However, the phenotype observed in the *Tfpi*[−/−] embryos is similar in several aspects to that observed in embryos lacking components of β-catenin signaling pathways, including Gpr124, where development of glomeruloid bodies and associated pathology have been extensively documented in the embryonic brain with normal vascular development in other tissues.[25,33,53] Therefore, we considered the possibility that the absence of TFPI and consequent excess thrombin production alters β-catenin signaling within the developing brain.

17

The two principal effectors of β-catenin signaling that control cerebral vascular development are Wnt7a/b or Norrin binding to frizzled/LRP receptor complexes.[54] Wnt7a/7b interacts with Gpr124, Lrp5/6, and Reck to promote vascular development predominantly in the forebrain and spinal cord, while Norrin interacts with Tetraspanin 12 and Lrp5 to promote developmental angiogenesis predominantly in the hindbrain and spinal cord.[54] Deficiency of components of these pathways in mice produce CNS-specific vascular defects that closely mimic some features observed in *Tfpi*⁻/⁻ embryos but differ in the spatial location of glomeruloid body formation. For example, the vasculature in *Tfpi*⁻/⁻ embryos was affected in the forebrain, midbrain, hindbrain, and spinal cord compared to defects in the β-catenin pathway featuring localized effects in the embryonic forebrain (Wnt7a/7b) or hindbrain (Norrin). This suggested the possibility that excess thrombin produced in the *Tfpi*⁻/⁻ embryos may degrade one or more of the extracellular effectors of the β-catenin signaling complexes. In support of this hypothesis, it has been reported that thrombin degrades Gpr124 by cleaving at two specific sites within its extracellular domain.[34] However, staining for the extracellular domain of Gpr124 in the brain of *Tfpi*⁻/⁻ embryos revealed the presence of Gpr124 on normal appearing vasculature and vessels within glomeruloid bodies. Further studies investigating how coagulation protease activity may intersect with effectors of β-catenin signaling pathways will enhance our understanding of the complex pathways regulating cerebral vascular development and define potential links responsible for the similar defects in cerebrovascular development observed in the embryos lacking TFPI and components of the β-catenin pathway.

In summary, TFPI is an inhibitor of TF-FVIIa and prothrombinase, two of the main catalytic complexes of the procoagulant response.[49] The presence of severe CNS vascular anomalies in

Tfpi$^{-/-}$ embryos implicates the coagulation system as a key player in angiogenic signaling pathways within the developing CNS in mice. Since the CNS pathology was fully rescued by the absence of FV, the modulation of thrombin production by TFPI likely drives the phenotype.

Authorship Contributions

S.A.M. Designed research, performed research, analyzed data and wrote the paper. R.J.W designed research, analyzed data and wrote the paper. A.C.C. performed research and wrote the paper. N.D.M performed research. A.E.S. analyzed data and wrote the paper. M.Z. performed research. D.G. analyzed data and wrote the paper. H.W. analyzed data and wrote the paper. A.E.M. designed research, analyzed data, and wrote the paper.

Disclosure of Conflicts of Interest

Conflict of Interest Statement: AEM receives research funding from Novo Nordisk and has received honoraria for serving on Novo Nordisk Advisory Boards. The other authors have declared that no conflict of interest exists.

References

1. Rao LV, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. *Blood*. 1987;69(2):645-651.
2. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. *Nature*. 1989;338(6215):518-520.
3. Broze GJ, Jr., Miletich JP. Characterization of the inhibition of tissue factor in serum. *Blood*. 1987;69(1):150-155.
4. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. *Proc Natl Acad Sci U S A*. 1977;74(12):5260-5264.
5. Baugh RJ, Broze GJ, Jr., Krishnaswamy S. Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. *J Biol Chem*. 1998;273(8):4378-4386.
6. Griffin CT, Srinivasan Y, Zheng YW, Huang W, Coughlin SR. A role for thrombin receptor signaling in endothelial cells during embryonic development. *Science*. 2001;293(5535):1666-1670.
7. Maroney SA, Ellery PE, Wood JP, Ferrel JP, Martinez ND, Mast AE. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)alpha and TFPIbeta. *J Thromb Haemost*. 2013;11(5):911-918.
8. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. *Blood*. 2005;105(6):2384-2391.
9. Rothmeier AS, Liu E, Chakrabarty S, et al. Identification of the integrin-binding site on coagulation factor VIIa required for proangiogenic PAR2 signaling. *Blood*. 2018;131(6):674-685.
10. Huang ZF, Higuchi D, Lasky N, Broze GJ, Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. *Blood*. 1997;90(3):944-951.
11. Chan JC, Carmeliet P, Moons L, et al. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. *J Clin Invest*. 1999;103(4):475-482.
12. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. *Proc Natl Acad Sci U S A*. 2013;110(44):17838-17843.
13. Coughlin SR. Thrombin signalling and protease-activated receptors. *Nature*. 2000;407(6801):258-264.
14. Wood JP, Petersen HH, Yu B, Wu X, Hilden I, Mast AE. TFPIalpha interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation. *Blood Adv*. 2017;1(27):2692-2702.
15. van Doorn P, Rosing J, Wielders SJ, Hackeng TM, Castoldi E. The C-terminus of tissue factor pathway inhibitor-alpha inhibits factor V activation by protecting the Arg(1545) cleavage site. *J Thromb Haemost*. 2017;15(1):140-149.
16. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. *Nature*. 1998;394(6694):690-694.
17. Ellery PE, Maroney SA, Cooley BC, et al. A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development. *Blood*. 2015;125(26):4078-4084.

18.   Cui J, O'Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. *Nature*. 1996;384(6604):66-68.

19.   Yang TL, Cui J, Taylor JM, Yang A, Gruber SB, Ginsburg D. Rescue of fatal neonatal hemorrhage in factor V deficient mice by low level transgene expression. *Thromb Haemost*. 2000;83(1):70-77.

20.   Sun H, Yang TL, Yang A, Wang X, Ginsburg D. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. *Blood*. 2003;102(8):2856-2861.

21.   Theiler K. The house mouse : atlas of embryonic development; 1989.

22.   Nystrom S. Pathological changes in blood vessels of human glioblastoma multiforme. Comparative studies using plastic casting, angiography, light microscopy and electron microscopy, and with reference to some other brain tumours. *Acta Pathol Microbiol Scand Suppl*. 1960;49(Suppl 137):1-83.

23.   Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. *J Neurosurg*. 1996;85(6):1078-1084.

24.   Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin--a glycoprotein from basement membranes. *J Biol Chem*. 1979;254(19):9933-9937.

25.   Vallon M, Chang J, Zhang H, Kuo CJ. Developmental and pathological angiogenesis in the central nervous system. *Cell Mol Life Sci*. 2014;71(18):3489-3506.

26.   Puelles L, Martinez-Marin R, Melgarejo-Otalora P, Ayad A, Valavanis A, Ferran JL. Patterned Vascularization of Embryonic Mouse Forebrain, and Neuromeric Topology of Major Human Subarachnoidal Arterial Branches: A Prosomeric Mapping. *Front Neuroanat*. 2019;13:59.

27.   Frank RN, Turczyn TJ, Das A. Pericyte coverage of retinal and cerebral capillaries. *Invest Ophthalmol Vis Sci*. 1990;31(6):999-1007.

28.   Shepro D, Morel NM. Pericyte physiology. *FASEB J*. 1993;7(11):1031-1038.

29.   Thion MS, Ginhoux F, Garel S. Microglia and early brain development: An intimate journey. *Science*. 2018;362(6411):185-189.

30.   Goldmann T, Wieghofer P, Jordao MJ, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. *Nat Immunol*. 2016;17(7):797-805.

31.   Arnold T, Betsholtz C. The importance of microglia in the development of the vasculature in the central nervous system. *Vasc Cell*. 2013;5(1):4.

32.   Westrick RJ, Cleuren A, Martinez ND, et al. Platelet FV Deficiency Restores Survival of TFPI Null Mice Independently of Plasma FV. *Blood*. 2017;130(Supplement 1):365-365.

33.   Cullen M, Elzarrad MK, Seaman S, et al. GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood-brain barrier. *Proc Natl Acad Sci U S A*. 2011;108(14):5759-5764.

34.   Vallon M, Aubele P, Janssen KP, Essler M. Thrombin-induced shedding of tumour endothelial marker 5 and exposure of its RGD motif are regulated by cell-surface protein disulfide-isomerase. *Biochem J*. 2012;441(3):937-944.

35.   Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. *J Cell Physiol*. 1997;173(2):206-210.

36.   Korn C, Augustin HG. Mechanisms of Vessel Pruning and Regression. *Dev Cell*. 2015;34(1):5-17.

37.   Gautam J, Zhang X, Yao Y. The role of pericytic laminin in blood brain barrier integrity maintenance. *Sci Rep*. 2016;6:36450.

38.   Mosser CA, Baptista S, Arnoux I, Audinat E. Microglia in CNS development: Shaping the brain for the future. *Prog Neurobiol*. 2017;149-150:1-20.

39.   Stremmel C, Schuchert R, Wagner F, et al. Yolk sac macrophage progenitors traffic to the embryo during defined stages of development. *Nat Commun*. 2018;9(1):75.

40.   Vanlandewijck M, He L, Mae MA, et al. A molecular atlas of cell types and zonation in the brain vasculature. *Nature*. 2018;554(7693):475-480.

41.   Bennett ML, Bennett FC, Liddelow SA, et al. New tools for studying microglia in the mouse and human CNS. *Proc Natl Acad Sci U S A*. 2016;113(12):E1738-1746.

42.   Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. *Proc Natl Acad Sci U S A*. 2001;98(14):7742-7747.

43.   Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. *Thromb Res*. 2010;125 Suppl 2:S36-38.

44.   Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. *Am J Pathol*. 1989;134(5):1087-1097.

45.   Hembrough TA, Ruiz JF, Swerdlow BM, et al. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. *Blood*. 2004;103(9):3374-3380.

46.   Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. *J Biol Chem*. 2001;276(15):12241-12248.

47.   Holroyd EW, Delacroix S, Larsen K, et al. Tissue factor pathway inhibitor blocks angiogenesis via its carboxyl terminus. *Arterioscler Thromb Vasc Biol*. 2012;32(3):704-711.

48.   Maroney SA, Ferrel JP, Collins ML, Mast AE. Tissue factor pathway inhibitor-gamma is an active alternatively spliced form of tissue factor pathway inhibitor present in mice but not in humans. *J Thromb Haemost*. 2008;6(8):1344-1351.

49.   Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. *Blood*. 2014;123(19):2934-2943.

50.   Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. *Blood*. 1998;92(9):3035-3041.

51.   Soifer SJ, Peters KG, O'Keefe J, Coughlin SR. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. *Am J Pathol*. 1994;144(1):60-69.

52.   Connolly AJ, Ishihara H, Kahn ML, Farese RV, Jr., Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. *Nature*. 1996;381(6582):516-519.

53.   Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA. Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis. *Proc Natl Acad Sci U S A*. 2009;106(2):641-646.

54.   Wang Y, Cho C, Williams J, et al. Interplay of the Norrin and Wnt7a/Wnt7b signaling systems in blood-brain barrier and blood-retina barrier development and maintenance. *Proc Natl Acad Sci U S A*. 2018;115(50):E11827-E11836.

23

Figure Legends

Figure 1. E15.5 sagittal sections of *Tfpi*$^{-/-}$ brains at the level of the interpeduncular fossa (IPF) displayed large areas of cellular death and associated hemorrhage surrounded by vascular anomalies called glomeruloid bodies. (A) H&E stain showed the *Tfpi*$^{+/+}$ brain filling the entire cavity of the skull while the *Tfpi*$^{-/-}$ brain was smaller and underdeveloped with a large space between the brain and the calvarium. Arrows identify enlarged congested blood vessels in the *Tfpi*$^{-/-}$ brain (bar=100μm). (B) High magnification of the enlarged congested vessels in the *Tfpi*$^{-/-}$ brain identified them as glomeruloid bodies (bar=30μm). H&E: A multi-compartmental vessel with pink amorphous material suggestive of fibrin clot and lumens containing nucleated RBCs. Trichrome (TRI): A multi-compartmental vessel with septa containing collagen and nucleated RBCs within the lumens. MSB: A multi-compartmental vessel containing numerous yellow nucleated RBCs and pink to red fibrin lining the lumens. (C) MSB staining highlighted the brain pathology of *Tfpi*$^{-/-}$ embryos. The dotted black line encircles a large area of cell death (pyknotic nuclei and loss of parenchyma) and hemorrhage (pools of yellow stained nucleated RBCs). Arrows identify numerous glomeruloid bodies surrounding the area of necrosis and hemorrhage (bar=100μm).

Figure 2. Glomeruloid bodies had fibrin deposition and endothelial cell disarray. (A) Sagittal sections of E15.5 littermate brains stained with anti-fibrin(ogen). The inset of the *Tfpi*$^{-/-}$ brain shows fibrin(ogen) deposits inside and outside the vascular compartment, suggesting vasculature leakage around the glomeruloid bodies (arrows). Areas of cell death characterized by pyknotic nuclei were adjacent to the glomeruloid bodies (arrowheads). Fibrin(ogen) deposition was not observed in the *Tfpi*$^{+/+}$ brain (bar=100μm, inset bar=30μm). (B) Sagittal sections of

24

E15.5 littermate brains stained with an anti-laminin antibody. Numerous glomeruloid bodies throughout multiple areas of the *Tfpi*[−/−] brain were outlined by laminin staining of the basement membrane. Glomeruloid bodies were not present in *Tfpi*[+/+] brain (bar=100μm, inset bar=30μm). (C) Immunofluorescence of littermate brains stained for laminin (red/yellow), for thrombomodulin (green), and with DAPI stained nuclei (blue). *Tfpi*[+/+] brain had well-organized vasculature with thrombomodulin-stained endothelial cells internal to the laminin-stained vascular basement membrane. *Tfpi*[−/−] embryo brain had disorganized multi-lobular vasculature containing thrombomodulin-stained endothelial cells in disarray surrounded by a laminin-stained basement membrane (bar=10μm).

Figure 3. Glomeruloid bodies were present in the forebrain, hindbrain, and spinal cord of E14 *Tfpi*[−/−] brain. (A) Coronal sections of anterior forebrain, posterior forebrain, and hindbrain stained for laminin revealed glomeruloid bodies throughout the brain parenchyma. In the sections shown, the anterior forebrain section was at the beginning of the lateral ganglionic eminence. The posterior forebrain section was near its junction with the midbrain as indicated by the presence of the Aqueduct of Sylvius, the lateral ventricle, the choroid plexus, and the third ventricle. The hindbrain section was at the level of the Aqueduct of Sylvius and fourth ventricle. (B) Magnification of the boxed areas in (A). Anterior forebrain inset: glomeruloid bodies were present at the bottom of the brain entering from the pial vasculature and in the subventricular zone adjacent to the lateral ventricle (arrows) (bar=60μm). Posterior forebrain inset: glomeruloid bodies were present throughout the brain parenchyma and adjacent to areas of cell death (dotted black line). Large glomerular bodies originate from pial vessels adjacent to the lateral ventricle (arrow) (bar=80μm). Hindbrain inset: glomeruloid bodies were present throughout the

25

parenchyma, and pial vessels at the pia-brain interface were disorganized (arrows) (bar=100μm). Spinal cord: glomeruloid bodies were present in the spinal cord (SC). Adjacent to the spinal cord is the vertebral body primordium (VBP) (bar=100μm). Corresponding coronal sections from a *Tfpi*$^{+/+}$ littermate are presented in Supplemental Figure 2.

Figure 4. The pial vessels in the *Tfpi*$^{-/-}$ embryos were disorganized and produce glomeruloid bodies upon penetrating into the brain parenchyma. Meninges and pial vessels of E16 *Tfpi*$^{+/+}$ and *Tfpi*$^{-/-}$ littermates stained for laminin. (A) The meninges of the *Tfpi*$^{+/+}$ brain are well organized with normal vasculature seen entering the brain parenchyma (arrow). A prominent feature of the *Tfpi*$^{-/-}$ meninges is the large layer of abnormal vascular endothelial cells piled up in the pia mater that formed glomeruloid bodies upon entering the brain parenchyma (arrow) (bar=100μm). (B) The meningeal layers are identified by numbered brackets: 1) skeletogenous layer of the future skull; 2) dura mater; 3) arachnoid mater; 4) pia mater; and 5) brain parenchyma. Formation of the meninges was delayed in *Tfpi*$^{-/-}$ embryos when compared to *Tfpi*$^{+/+}$ littermates. Vasculature was absent in the arachnoid layer of *Tfpi*$^{-/-}$ embryos, which lacks definition of the impermeable outer layer that prevents passage of CSF from the subarachnoid space (bar=30μm).

Figure 5. Pericytes and microglial cells were present within glomeruloid bodies in the E15.5 *Tfpi*$^{-/-}$ brain. (A) Immunofluorescence of brain vasculature from littermates stained for PDGFRβ (red), for thrombomodulin (green), and with DAPI stained nuclei (blue). Occasional pericytes (red) were present along vasculature within the *Tfpi*$^{+/+}$ brain parenchyma. The glomeruloid bodies within the *Tfpi*$^{-/-}$ embryo had numerous pericytes associated with the aggregated endothelial cells (bar=10μm). (B) Immunofluorescence of brain vasculature from littermates

26

stained for IBA-1 (red/yellow), for thrombomodulin (green), and with DAPI stained nuclei

(blue). IBA-1 expressing microglial cells were associated with endothelial cells in the $Tfpi^{+/+}$ and

$Tfpi^{-/-}$ embryos with no discernible differences between genotypes (bar=10μm).

Figure 6. E15.5 $Tfpi^{-/-}$ embryos lacking FV have normal cerebral vasculature. (A) (A)

Trichrome stained midbrain from a $F5^{+/-} Tfpi^{-/-}$ embryo had a large area of hemorrhage

(asterisk) and necrosis surrounded by glomeruloid bodies, essentially identical to that observed

in the $Tfpi^{-/-}$ embryos. In contrast, $F5^{-/-} Tfpi^{-/-}$ embryos had normal brain vasculature without

evidence of glomeruloid bodies, hemorrhage, or cellular death. Fibrin(ogen) stained midbrain

from a $F5^{+/-} Tfpi^{-/-}$ embryo demonstrated vascular staining. Glomeruloid bodies were seen

surrounded by fibrinogen (brackets) leaking from the abnormal vessels. The dotted line

delineated the brain tissue with massive cell death (right) from that of the living cells (left).

Normal architecture of the $F5^{-/-} Tfpi^{-/-}$ embryo brain displayed normal vasculature without

fibrinogen leakage. Laminin staining of the $F5^{+/-} Tfpi^{-/-}$ brain revealed numerous glomeruloid

bodies throughout the brain parenchyma (arrows point to three glomeruloid bodies). The dotted

line delineates cell death (right) from living cells (left). The $F5^{-/-} Tfpi^{-/-}$ had normal vasculature

with laminin stained basement membrane. IPF= interpeduncular fossa; bar=100μm. (B)

Trichrome stain of pial vessels (arrows) penetrating the brain parenchyma in the $F5^{+/-} Tfpi^{-/-}$

embryo (left) and the $F5^{-/-} Tfpi^{-/-}$ embryo (right). The penetrating vasculature of the $F5^{+/-} Tfpi^{-/-}$

embryo revealed glomeruloid bodies advancing from the disorganized pia mater while the

vasculature from the $F5^{-/-} Tfpi^{-/-}$ embryo is organized with parallel walls. (bar=50μm).

(C) Trichrome stained sections from $F5^{-/-} Tfpi^{-/-}$ embryos carrying the $F5^{LiverTg}$. Rare

glomeruloid bodies were observed in the midbrain of one embryo (arrows) and spinal cord of

27

another embryo (sc; square). Minor hemorrhage is present in the spinal cord but is not associated with cell death or inflammation. No pathology was observed in three other $F5^{-/-}$ $F5^{LiverTg}$ $Tfpi^{-/-}$ embryos (bar=100μm).

Figure 7. Gpr124 is present in glomeruloid bodies of E13.5 *Tfpi*$^{-/-}$ brain. Forebrain sections from *Tfpi*$^{+/+}$ and *Tfpi*$^{-/-}$ littermates were stained for the extracellular domain of Gpr124 (red), for thrombomodulin (THBD) (green) and with DAPI stained nuclei (blue) to depict the PNVP of the anterior forebrain and the adjacent lateral ventricle. Gpr124 stains well-organized vasculature in the *Tfpi*$^{+/+}$ brain and the disorganized vasculature penetrating from the PNVP into the brain parenchyma in the *Tfpi*$^{-/-}$ brain. In the overlay, thrombomodulin stains the endothelial cells in the same pattern as Gpr124 in both embryos. Auto fluorescence of the embryonic nucleated RBCs is observed within the vasculature of both embryos and areas of hemorrhage in the *Tfpi*$^{-/-}$ embryo (bar=30μm).

A

Tfpi[+/+]

H&E

IPF

Tfpi[-/-]

IPF

B

Tfpi[-/-]

H&E

TRI

MSB

C

Tfpi[-/-]

MSB

Figure 1 FINAL

A

Tfpi+/+

IPF

Tfpi−/−

IPF

Tfpi−/−

B

Tfpi+/+

IPF

Tfpi−/−

IPF

Tfpi−/−

C

Tfpi+/+

Tfpi−/−

LAMININ / THBD / DAPI

Figure 2 FINAL

A Anterior forebrain   Posterior forebrain   Hindbrain

B

Anterior forebrain inset

Posterior forebrain inset

Hindbrain inset

Spinal cord

VBP   SC

Figure 3 FINAL

A

Tfpi⁺/⁺

Tfpi⁻/⁻

B

Tfpi⁺/⁺

1
2
3
4
5

Tfpi⁻/⁻

1
2
3
4
5

Figure 4 FINAL

A

Tfpi^{+/+}   Tfpi^{−/−}

PDGFRβ / THBD / DAPI

B

Tfpi^{+/+}   Tfpi^{−/−}

IBA1 / THBD / DAPI

Figure 5 FINAL

A

F5$^{+/-}$ Tfpi$^{-/-}$ F5$^{-/-}$ Tfpi$^{-/-}$

Trichrome

IPF   IPF

Fibrinogen

IPF   IPF

Laminin

IPF   IPF

B

F5$^{+/-}$ Tfpi$^{-/-}$ F5$^{-/-}$ Tfpi$^{-/-}$

Laminin

C

F5$^{-/-}$ F5^{LiverTg} Tfpi$^{-/-}$

Trichrome

SC

Figure 6 FINAL

Tfpi⁺/⁺

Tfpi⁻/⁻

Figure 7 FINAL